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Objectives The aim of this study was to assess the effects of different proton pump inhibitors (PPIs) on the steady-state
pharmacokinetics and pharmacodynamics of clopidogrel.
Background Metabolism of clopidogrel requires cytochrome P450s (CYPs), including CYP2C19. However, PPIs may inhibit
CYP2C19, potentially reducing the effectiveness of clopidogrel.
Methods A randomized, open-label, 2-period, crossover study of healthy subjects (n  160, age 18 to 55 years, homozy-
gous for CYP2C19 extensive metabolizer genotype, confined, standardized diet) was conducted. Clopidogrel 75
mg with or without a PPI (dexlansoprazole 60 mg, lansoprazole 30 mg, esomeprazole 40 mg, or, as a positive
control to maximize potential interaction and demonstrate assay sensitivity, omeprazole 80 mg) was given daily
for 9 days. Pharmacokinetics and pharmacodynamics were assessed on days 9 and 10. Pharmacodynamic end-
points were vasodilator-stimulated phosphoprotein P2Y12 platelet reactivity index, maximal platelet aggregation
to 5 and 20 mol/l adenosine diphosphate, and VerifyNow P2Y12 platelet response units.
Results Pharmacokinetic and pharmacodynamic responses with omeprazole demonstrated assay sensitivity. The area
under the curve for clopidogrel active metabolite decreased significantly with esomeprazole but not with dexlansopra-
zole or lansoprazole. Similarly, esomeprazole but not dexlansoprazole or lansoprazole significantly reduced the effect
of clopidogrel on vasodilator-stimulated phosphoprotein platelet reactivity index. All PPIs decreased the peak plasma
concentration of clopidogrel active metabolite (omeprazole  esomeprazole  lansoprazole  dexlansoprazole) and
showed a corresponding order of potency for effects on maximal platelet aggregation and platelet response units.
Conclusions Generation of clopidogrel active metabolite and inhibition of platelet function were reduced less by the coadmin-
istration of dexlansoprazole or lansoprazole with clopidogrel than by the coadministration of esomeprazole or
omeprazole. These results suggest that the potential of PPIs to attenuate the efficacy of clopidogrel could be
minimized by the use of dexlansoprazole or lansoprazole rather than esomeprazole or omeprazole. (A Study of
the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmaco-
kinetics and Pharmacodynamics of Clopidogrel in Healthy Participants; NCT00942175) (J Am Coll Cardiol
2012;59:1304–11) © 2012 by the American College of Cardiology Foundation
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April 3, 2012:1304–11 PPI Effects on Clopidogrel PK and PDThe co-administration of proton pump inhibitors (PPI)
with clopidogrel reduces the risk for gastrointestinal bleed-
ing associated with the antiplatelet effects of clopidogrel (1).
There are conflicting data as to whether PPIs have the
potential to reduce the effectiveness of clopidogrel (1).
Clopidogrel is a prodrug that requires metabolism by
hepatic cytochrome P450 (CYP) enzymes, including
CYP2C19, to an active metabolite that blocks platelet
P2Y12 adenosine diphosphate (ADP) receptors. Because
PIs are known inhibitors of CYP2C19 (1), they may
revent the conversion of clopidogrel to its active metabolite
clopidogrelAM). However, because not all PPIs inhibit
CYP2C19 to the same extent (2–4), the potential for a
clinically relevant drug-drug interaction with clopidogrel
may not be generalized to all PPIs. The present random-
ized, open-label, 2-period, crossover study was therefore
designed to determine the effects of 4 different PPIs
(dexlansoprazole, lansoprazole, omeprazole, and esomepra-
zole) on the steady-state pharmacokinetics (PK) and phar-
macodynamics (PD) of clopidogrel.
Methods
The study design, enrollment criteria, clopidogrel PK and
PD, and statistics are described in detail in the Online
Appendix. To eliminate variables known to influence clopi-
dogrel and/or PPI metabolism, homozygous CYP2C19
extensive metabolizer genotype healthy subjects were en-
rolled and confined in a clinical research unit.
Results
Study population. The disposition of subjects is shown in
Online Figure 1. Demographic characteristics of the 160
subjects who were randomized to receive study drug are
shown in Table 1. One hundred fifty subjects completed
study drug and all study visits (Online Fig. 1).
PK of clopidogrel in the presence and absence of PPIs.
Clinically relevant daily doses of clopidogrel (75 mg),
dexlansoprazole (60 mg), lansoprazole (30 mg), and esome-
prazole (40 mg) were used, and the timing of PPI dosing
relative to clopidogrel was adjusted to synchronize times to
reach peak concentration. Omeprazole 80 mg/day, a potent
inhibitor of CYP2C19, was used as a positive control for the
interaction of a PPI with clopidogrel PK. As expected, peak
plasma concentration of clopidogrelAM and area under the
plasma concentration–time curve (AUCt) were lower when
lopidogrel was administered with omeprazole 80 mg com-
ared with clopidogrel alone (Table 2, Figs. 1B and 1D).
and is a research collaborator with PLx Pharma and Takeda and served as the Chair of the
COGENT trial. Dr. Michelson has been a member of the data safety monitoring boards
of clinical trials sponsored by Eli Lilly/Daiichi Sankyo and Sanofi Aventis/Bristol-Myers
Squibb. All other authors have reported that they have no relationship relevant to the
contents of this paper to disclose.Manuscript received July 12, 2011; revised manuscript received December 5, 2011,
accepted December 19, 2011.ClopidogrelAM AUCt on day
of the administration of clopi-
ogrel with dexlansoprazole or
ansoprazole was similar to that
bserved on day 9 of the adminis-
ration of clopidogrel alone (Table 2,
ig. 1). In contrast, clopidogrelAM
AUCt on day 9 of the administra-
ion of clopidogrel with esomepra-
ole was reduced compared with
hat observed at 9 days of the ad-
inistration of clopidogrel alone
Fig. 1B, Table 2).
Relative to clopidogrel alone, all
PIs decreased the peak plasma
oncentration of clopidogrelAM
(omeprazole  esomeprazole 
lansoprazole  dexlansoprazole)
Figs. 1C and 1D).
Clopidogrel was rapidly ab-
orbed (median time to reach peak
oncentration for intact clopidogrel
h), and this was unaffected by
ansoprazole, dexlansoprazole,
meprazole, or esomeprazole (data
ot shown).
D of clopidogrel in the presence and absence of PPIs.
meprazole 80 mg, the positive control, when coadministered
ith clopidogrel, caused significant changes in vasodilator-
timulated phosphoprotein (VASP) platelet reactivity index
PRI), light transmission aggregation maximal platelet aggrega-
ion (MPA), and VerifyNow P2Y12 (Accumetrics, Inc., San
iego, CA) platelet response units (PRU) compared with
lopidogrel alone (Figs. 2, 3, and 4, Tables 3, 4, and 5).
VASP P2Y12 ASSAY. The least squares mean differences in
ASP PRI 24 h after 9 days administration of clopidogrel with
ansoprazole or clopidogrel with dexlansoprazole compared
ith clopidogrel alone were small (4.1% and 2.0%, respec-
ively) with 90% confidence interval upper boundaries 15%
Table 3, Fig. 2), that is, less than the pre-specified upper
o-effect boundary. In contrast, the difference in VASP PRI 24 h
fter 9 days administration of clopidogrel with esomeprazole
ompared with clopidogrel alone was larger, 11.4%, and its 90%
onfidence interval upper boundary, 15.71%, extended beyond the
pper no-effect boundary of 15% (Table 3, Fig. 2). The magni-
ude of the change in VASP PRI with esomeprazole (11.4%) was
imilar to that observed with omeprazole (11.0%).
LIGHT TRANSMISSION AGGREGATION. MPA in response
o ADP 5 mol/l 24h after 9 days coadministration of
clopidogrel with dexlansoprazole was not significantly
different from MPA after clopidogrel alone. As with
dexlansoprazole, the difference in MPA after clopidogrel
with lansoprazole compared with clopidogrel alone was
also small but, unlike that with dexlansoprazole, was
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
AUCt  area under the
plasma concentration–time
curve
clopidogrelAM  clopidogrel
active metabolite
CYP  cytochrome P450
HPR  high on-treatment
platelet reactivity
MPA  maximal platelet
aggregation
PD  pharmacodynamics
PK  pharmacokinetics
PPI  proton pump
inhibitor
PRI  platelet reactivity
index
PRU  platelet response
units
VASP  vasodilator-
stimulated phosphoproteinstatistically significant. Similar results for both dexlanso-
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PPI Effects on Clopidogrel PK and PD April 3, 2012:1304–11prazole and lansoprazole were observed when ADP 20
mol/l was used as the agonist for platelet aggregation
Table 4). In contrast, the coadministration of esomepra-
ole with clopidogrel led to larger increases in ADP 5
mol/l MPA, which was similar to the least squares
ean difference observed with versus without the positive
ontrol, omeprazole (Table 4). Likewise, large, numeri-
ally similar differences were seen for both omeprazole
nd esomeprazole when ADP 20 mol/l was used as the
agonist for platelet aggregation (Table 4). Similar results
were obtained analyzing the percent inhibition of platelet
aggregation (Table 4).
Summary of Demographic and Baseline Characteristics for All PPITable 1 Su mary of Demographic and Baseline Characteristics
Characteristic
PPI Group 1:
Lansoprazole
(n  40)
PPI Group
Dexlansopraz
(n  40)
Sex
Male 20 (50.0%) 20 (50.0%
Female 20 (50.0%) 20 (50.0%
Age (yrs) 32.8 6.48 (20–47) 35.7 7.92 (2
Race
White 40 (100.0%) 39 (97.5%
American Indian or Alaska
Native
0 0
Native Hawaiian or Other
Pacific Islander
0 1 (2.5%)
Ethnicity
Hispanic or Latino 40 (100.0%) 38 (95.0%
Not Hispanic or Latino 0 2 (5.0%)
Weight (kg) 70.1 10.29 70.8 9.9
Height (cm) 164.3 8.91 165.0 8.4
BMI (kg/m2) 25.9 2.26 26.0 2.4
Values are n (%) or mean  SD (range).
BMI  body mass index; PPI  proton pump inhibitor.
ClopidogrelAM Pharmacokinetics With and Without PPIsTable 2 ClopidogrelAM Pharmacokinetics With and Without PPI
Variable Clopidogrel With PPI
Lansoprazole 30 mg
Tmax (h) 0.50 0.50/4.00 (38)
Cmax (ng/ml) 30.01 15.26 (38)
AUCt (ng · h/ml) 36.42 10.82 (38)
Dexlansoprazole 60 mg
Tmax (h) 0.50 0.50/1.50 (36)
Cmax (ng/ml) 29.33 12.4 (36)
AUCt (ng · h/ml) 37.75 13.13 (36)
Esomeprazole 40 mg
Tmax (h) 0.50 0.50/1.50 (38)
Cmax (ng/ml) 24.69 10.64 (38)
AUCt (ng · h/ml) 31.23 9.94 (38)
Omeprazole 80 mg
Tmax (h) 0.50 0.50/3.00 (38)
Cmax (ng/ml) 22.55 10.68 (38)
AUCt (ng · h/ml) 26.28 8.80 (38)
Values are medianminimum/maximum (n) for Tmax and mean SD (n) for Cmax and AUCt. *Po
ower no-effect boundary limit for the 90% CI of the ratio was 0.80, and the upper no-effect boun
AUCt area under the plasma concentration–time curve; CI confidence interval; clopidogrelAM c
Tmax  time to reach peak concentration.VERIFYNOW P2Y12 ASSAY. Compared with clopidogrel alone,
the increases in PRU when clopidogrel was coadministered
with dexlansoprazole, lansoprazole, omeprazole, or esome-
prazole were statistically significant; however, these changes
were greatest for omeprazole and esomeprazole compared
with dexlansoprazole and lansoprazole (Table 5). Results
using VerifyNow P2Y12 percent inhibition to assess the
effect of clopidogrel with and without PPIs were similar to
results obtained using PRU (Online Table 5).
HIGH ON-TREATMENT PLATELET REACTIVITY (HPR). The
frequency of HPR as defined by the recommended cutoffs
sAll PPI Groups
PPI Group 3:
Omeprazole
(n  40)
PPI Group 4:
Esomeprazole
(n  160) Overall
20 (50.0%) 20 (50.0%) 80 (50.0%)
20 (50.0%) 20 (50.0%) 80 (50.0%)
34.0 7.40 (22–51) 33.3 7.10 (20–49) 33.9 7.26 (20–53)
39 (97.5%) 39 (97.5%) 157 (98.1%)
1 (2.5%) 1 (2.5%) 2 (1.3%)
0 0 1 (0.6%)
38 (95.0%) 40 (100.0%) 156 (97.5%)
2 (5.0%) 0 4 (2.5%)
68.6 7.44 71.6 10.83 70.3 9.69
162.3 8.40 164.3 8.73 163.9 8.61
26.1 2.16 26.4 2.50 26.1 2.32
Clopidogrel Alone Ratio* 90% CI
0 0.50/1.50 (38)
4 12.55 (38) 0.70 0.611–0.803
9 10.02 (38) 0.86 0.802–0.916
0 0.50/1.50 (36)
5 15.7 (36) 0.73 0.652–0.827
5 14.69 (36) 0.91 0.857–0.967
0 0.50/1.50 (38)
7 22.91 (38) 0.68 0.506–0.909
5 18.79 (38) 0.84 0.644–1.093
0 0.50/1.00 (38)
5 12.46 (38) 0.56 0.488–0.635
8 12.04 (38) 0.69 0.644–0.749
ates for ratios of the central values for the natural logarithms of Cmax and AUCt. The pre-specified
it was 1.25.Groupfor
2:
ole
)
)
2–53)
)
)
5
9
1s
0.5
39.1
41.6
0.5
38.8
41.2
0.5
40.9
42.3
0.5
38.2
37.7
int estim
dary limlopidogrel active metabolite; Cmax peak plasma concentration; PPI proton pump inhibitor;
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April 3, 2012:1304–11 PPI Effects on Clopidogrel PK and PDFigure 1 Pharmacokinetics of ClopidogrelAM
Mean (plus symbol), median (bar), and 5th (lower whisker), 25th (lower boundary of box), 75th (upper boundary of box), and 95th (upper whisker) percentiles for
area under the plasma concentration–time curve (AUCt) (A) and peak plasma concentration (Cmax) (C) of the active metabolite of clopidogrel (clopidogrelAM). (B,D)
Ratios of the central values with and without proton pump inhibitors and corresponding 90% confidence intervals. Dashed lines represent 0.80 and 1.25 no-effect bound-
aries. Clop  clopidogrel; DPZ  dexlansoprazole; EPZ  esomeprazole; LPZ  lansoprazole; OPZ  omeprazole.Figure 2 Pharmacodynamics: VASP P2Y12 PRI
(A) Vasodilator-stimulated phosphoprotein (VASP) platelet reactivity index (PRI) (box and whisker limits as in Fig. 1). (B) Least squares (LS) mean differences
with and without proton pump inhibitors and corresponding 90% confidence intervals. Dashed line represents upper no-effect boundary. Abbreviations as in Figure 1.
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PPI Effects on Clopidogrel PK and PD April 3, 2012:1304–11Figure 3 Pharmacodynamics: Light Transmission Aggregation in Response to 5 and 20 mol/l ADP
Maximal platelet aggregation with 5 mol/l (A) and 20 mol/l (B) adenosine diphosphate (ADP) (box and whisker limits as in Fig. 1).
(B,D) Least squares (LS) mean differences with and without proton pump inhibitors. Abbreviations as in Figure 1.Figure 4 Pharmacodynamics: Whole-Blood Platelet Aggregation by VerifyNow P2Y12 PRU
(A) VerifyNow P2Y12 platelet response units (PRU) (box and whisker limits as in Fig. 1).
(B) Least squares (LS) mean differences with and without proton pump inhibitors. Abbreviations as in Figure 1.
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April 3, 2012:1304–11 PPI Effects on Clopidogrel PK and PD(5) of VASP PRI 50%, MPA 5 mol/l ADP 46%, and
RU 236 was not significantly different 24 h after 9 days
dministration of clopidogrel with lansoprazole or dexlan-
oprazole compared with the administration of clopidogrel
lone (Table 6). In contrast, 24 h after 9 days administration
f clopidogrel with omeprazole, HPR by VASP PRI and
erifyNow P2Y12 PRU was significantly increased and, by
PA, approached significance compared with that after
lopidogrel alone. Additionally, HPR as defined by VASP
nd MPA 5 mol/l ADP was significantly greater 24 h after
9 days administration of clopidogrel with esomeprazole than
after clopidogrel alone (Table 6).
Discussion
The main PK findings are as follows. 1) The study design
and assay methods were appropriate to detect the effects of
VASP P2Y12 PRI in Clopidogrel-Treated SubjectsWith and Without 9 Days f PPI CoadministratioTable 3 VASP P2Y12 PRI in Cl pidogrel-TreaWith and Without 9 Days of PPI Co
PPI Group
PRI (%)
Clopidogrel Alone Clopidog
Lansoprazole 30 mg 42.3 14.6 46.4
Dexlansoprazole 60 mg 41.3 15.4 43.0
Esomeprazole 40 mg 46.5 17.3 58.0
Omeprazole 80 mg 47.9 15.7 59.1
Values are mean  SD. An LS mean difference with a 90% CI upper b
LS  least squares; PRI  platelet reactivity index; VASP  vasodil
Platelet Aggregation Measured by Light Transmission Aggregomet20 mol/l ADP in Clopidogrel-Treated Subjects With and Without 9Table 4 Platelet Aggregation M asured by Light Transmission20 mol/l ADP in Clopidogrel-Treated Subjects With a
PPI Group Clopidogrel Alone Clo
MPA (%)
ADP 5 mol/l
Lansoprazole 30 mg 28.1 6.76
Dexlansoprazole 60 mg 34.6 14.23
Esomeprazole 40 mg 29.3 10.41
Omeprazole 80 mg 34.2 12.32
ADP 20 mol/l
Lansoprazole 30 mg 36.7 9.11
Dexlansoprazole 60 mg 43.1 13.24
Esomeprazole 40 mg 39.3 13.22
Omeprazole 80 mg 43.5 14.00
IPA (%)
ADP 5 mol/l
Lansoprazole 30 mg 64.2 9.19
Dexlansoprazole 60 mg 54.0 21.12
Esomeprazole 40 mg 60.9 14.60
Omeprazole 80 mg 57.1 14.40
ADP 20 mol/l
Lansoprazole 30 mg 53.6 11.89
Dexlansoprazole 60 mg 43.2 19.87
Esomeprazole 40 mg 49.6 17.42
Omeprazole 80 mg 45.2 17.16Values are as mean  SD. *Calculated from LS means, which are provided in Online Table 7.
IPA  inhibition of platelet aggregation; MPA  maximal platelet aggregation; other abbreviations asPPIs on clopidogrel PK parameters, as evidenced by signif-
icant effects of coadministered omeprazole 80 mg. 2) Clopi-
dogrelAM AUCt values were equivalent when clopidogrel
as coadministered with or without dexlansoprazole 60 mg
r lansoprazole 30 mg, whereas clopidogrelAM AUCt values
were decreased when clopidogrel was coadministered with
omeprazole 80 mg or esomeprazole 40 mg compared with
clopidogrel alone. 3) All tested PPIs significantly decreased
peak plasma concentrations of clopidogrelAM, but esomepra-
zole and omeprazole did so to a greater degree than lansopra-
zole and dexlansoprazole. 4) ClopidogrelAM times to reach
peak concentration were not altered by any of the PPIs tested.
The main PD findings of this study are as follows. 1) The
study design and assay methods were appropriate to detect the
effects of PPIs on clopidogrel PD parameters, as evidenced by
significant effects of coadministered omeprazole 80 mg on
ubjects
nistration
us PPI LS Mean Difference 90% CI of Difference
.4 4.1 0.03 to 8.17
.5 2.0 0.86 to 4.95
.6 11.4 7.18 to 15.71
.9 11.0 6.52 to 15.56
ry of 15% was pre-specified to be significant.
mulated phosphoprotein; other abbreviations as in Tables 1 and 2.
Response to 5 ands PPI Coadministrationgometry in Response to 5 and
ithout 9 Days PPI Coadministration
el Plus PPI LS Mean Difference
p value
9.35 2.6 0.035
16.87 1.5 0.445
17.77 8.9 0.001
14.74 8.3 0.001
12.65 4.9 0.004
16.93 3.2 0.148
15.77 8.6 0.001
13.75 10.0 0.001
Percent change*
12.89 4.7 7.24
22.57 0.1 0.22
24.43 11.7 19.2
18.58 12.9 22.5
18.30 7.7 14.3
23.26 1.6 3.69
20.78 10.9 21.9
17.82 12.5 27.7nted S
admi
rel Pl
 16
 16
 14
 17ry inDayAggre
nd W
pidogr
30.8
36.2
38.2
42.5
41.6
46.3
47.9
53.5
59.5
53.9
49.3
44.2
46.0
41.6
38.7
32.8in Tables 1 and 2.
nd 3.
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PPI Effects on Clopidogrel PK and PD April 3, 2012:1304–11clopidogrel inhibition of VASP PRI, light transmission aggre-
gation MPA, and VerifyNow P2Y12 PRU. 2) VASP PRI
values were not different when clopidogrel was coadministered
with or without dexlansoprazole or lansoprazole, whereas
VASP PRI values were greater than the pre-specified no-effect
limit when clopidogrel was coadministered with omeprazole or
esomeprazole. 3) The coadministration of dexlansoprazole did
not have a significant effect on MPA, while the coadministra-
tion of lansoprazole had a small effect on MPA, numerically
similar to that of dexlansoprazole but statistically significant
compared with that of clopidogrel alone. In contrast, omepra-
zole and esomeprazole had larger, numerically similar, highly
significant effects on MPA. 4) All PPIs tested significantly
reduced clopidogrel inhibition of VerifyNow P2Y12 PRU.
However, the magnitudes of the effects of dexlansoprazole or
lansoprazole on VerifyNow P2Y12 PRU were approximately
one-third as large as the effects of omeprazole or esomeprazole.
By 3 distinct platelet function assays, the frequency of
subjects who would be categorized as at risk for ischemic or
thrombotic events after percutaneous coronary intervention
using the consensus group cutoffs (5) was unchanged by the
coadministration of dexlansoprazole or lansoprazole with
clopidogrel but increased by the coadministration of
omeprazole or esomeprazole with clopidogrel (Table 6).
Platelet Aggregation Measured by VerifyNow P2C opidogrel-Treated Subjects With and WithoutTable 5 Platelet Aggregation Measured by VClopidogrel-Treated Subjects With a
PPI Group
PRU
Clopidogrel Alone C
Lansoprazole 30 mg 114.9 56.4
Dexlansoprazole 60 mg 124.2 79.1
Esomeprazole 40 mg 121.1 50.6
Omeprazole 80 mg 133.0 67.6
Values are mean  SD.
PRU  platelet reactivity units; other abbreviations as in Tables 1 a
Change in HPR Status After the Coadministration of PPIs Withlopidogrel Comp red Wi h the Administra ion f Clopidogrel AloneTable 6 Change in HPR Status After the Coadministration of PClopidogrel Compared With the Administration of Clop
PPI Group n
Subjects Wit
to LPR After
HPR  VASP PRI 50%
Dexlansoprazole 60 mg 36
Lansoprazole 30 mg 38
Esomeprazole 40 mg 38
Omeprazole 80 mg 38
HPR  MPA 5 mol/l ADP46%
Dexlansoprazole 60 mg 36
Lansoprazole 30 mg 38
Esomeprazole 40 mg 38
Omeprazole 80 mg 37
HPR  PRU 236
Dexlansoprazole 60 mg 36
Lansoprazole 30 mg 38
Esomeprazole 40 mg 38
Omeprazole 80 mg 38*Exact p values calculated from binomial for numbers of discordant pairs.
HPR  high on-treatment platelet reactivity; LPR  low on-treatment platelet reactivity; other abbreviaIn addition to a drug-drug interaction via CYP2C19, it
has been proposed that PPIs may induce drug interactions
by elevating gastric pH and altering drug absorption rates
(1). The present study demonstrates that the rapid absorp-
tion of clopidogrel is unaffected by lansoprazole, dexlanso-
prazole, omeprazole, or esomeprazole.
Study strengths. This study’s randomized, 2-period, cross-
over design was a strength, as were enrollment criteria elimi-
nating variables known to influence clopidogrel and/or PPI
metabolism, including CYP2C19 polymorphisms and pro-
vided a uniform study population. Subjects were confined and
received a standardized, restricted diet, eliminating potential
confounding factors (including smoking, concurrent medica-
tions, and noncompliance with drug administration). Finally,
the study was well powered to detect both PK and PD effects,
as demonstrated by the statistically significant effects of the
positive control (omeprazole 80 mg).
Study limitations. Results for omeprazole 80 mg do not
necessarily apply to the more commonly used doses of 20
and 40 mg. Also, this study was conducted in confined
healthy volunteers, not patients, because this enabled us to
use a randomized, crossover design while controlling for
concurrent medications, diet, smoking, exercise, and other
factors. Last, for uniformity, this study included only
PRU inys of PPI CoadministrationNow 2Y12 PRU in
ithout 9 Days of PPI Coadministration
p Valuegrel Plus PPI LS Mean Difference
.8 71.3 17.0 0.001
.7 84.4 23.4 0.024
.6 55.4 56.5 0.001
.5 59.6 68.4 0.001
ith
el Alone
Converted
reatment
Subjects With LPR Converted
to HPR After PPI Treatment p Value*
4 1.000
6 0.289
13 0.021
12 0.035
4 0.375
2 0.500
11 0.001
11 0.057
2 0.500
2 0.500
5 0.062
13 0.002Y129 Daerify
nd W
lopido
131
146
177
201PIs W
idogr
h HPR
PPI T
5
2
3
3
1
0
0
3
0
0
0
1tions as in Tables 1, 3, 4, and 5.
p
o
c
s
e
l
5
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April 3, 2012:1304–11 PPI Effects on Clopidogrel PK and PDhomozygous CYP2C19 wt/wt extensive metabolizers; con-
sequently, our conclusions are limited to this population.
Conclusions
In this randomized, open-label, 2-period, crossover study of
healthy subjects, generation of clopidogrelAM and inhibition of
latelet function were reduced less by the coadministration
f dexlansoprazole or lansoprazole with clopidogrel than by the
oadministration of esomeprazole or omeprazole. These results
uggest that the potential of PPIs to attenuate clopidogrel
fficacy could be minimized by the use of dexlansoprazole or
ansoprazole rather than esomeprazole or omeprazole.
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